JALESIA AUSTIN: Open Payments
NPI 1205580834 · MAUMELLE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$932 in 31 payments from 15 companies in 2025. Trend: 2023 $206 · 2024 $1,238 · 2025 $932
Food & beverage: $932
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 2 | $165 |
| Vanda Pharmaceuticals Inc. | 1 | $124 |
| Lilly USA, LLC | 5 | $92 |
| Dexcom, Inc. | 1 | $91 |
| ABBVIE INC. | 4 | $81 |
| SANOFI-AVENTIS U.S. LLC | 1 | $67 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $58 |
| AstraZeneca Pharmaceuticals LP | 3 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
Products named: Wegovy, FANAPT, Dexcom G6 Transmitter, MOUNJARO, TZIELD, VRAYLAR, Kerendia, AIRSUPRA.
Industry payments across AR — which companies pay providers there.
